Oxford OTC Stock Story

OXBDF

Stock

USD 5.77 0.00 0.00%

Macroaxis Story

Oxford Biomedical is scheduled to announce its earnings tomorrow. As many investors are getting excited about healthcare space, it is fair to digest Oxford Biomedical as an investment option. Here we also measure the ability of Oxford Biomedical to meet its long-term debt obligations, such as interest payments on debt, the final principal payment on the debt, and any other fixed obligations like lease payments.

Published over a month ago

View all stories for Oxford Biomedical | View All Stories

Thinking to exit Oxford (OTC:OXBDF) based on its current debt commitments?

This firm has accumulated 9.34 M in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the firm is not taking enough advantage from borrowing.

The company holds a Beta of -0.027, which implies not very significant fluctuations relative to the market. Let's try to break down what Oxford's beta means in this case. As returns on the market increase, returns on owning Oxford Biomedical are expected to decrease at a much lower rate. During the bear market, Oxford Biomedical is likely to outperform the market. Even though it is essential to pay attention to Oxford Biomedical current trending patterns, it is always good to be careful when utilizing equity existing price patterns. Our philosophy towards forecasting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Oxford Biomedical exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Oxford Biomedical has an expected return of -0.7%. Please be advised to check Oxford Biomedical information ratio, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance to decide if Oxford Biomedical performance from the past will be repeated at some point in the near future.

Thinking to exit Oxford (OTC:OXBDF) based on its current debt commitments?

Oxford Biomedical financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Oxford Biomedical, including all of Oxford Biomedical's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Oxford Biomedical assets, the company is considered highly leveraged. Understanding the composition and structure of overall Oxford Biomedical debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it.

Please read more on our technical analysis page.

How important is Oxford Biomedical's Liquidity

Oxford Biomedical financial leverage refers to using borrowed capital as a funding source to finance Oxford Biomedical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Oxford Biomedical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Oxford Biomedical's total debt and its cash.

How does Oxford utilize its cash?

To perform a cash flow analysis of Oxford Biomedical, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Oxford Biomedical is receiving and how much cash it distributes out in a given period. The Oxford Biomedical cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Is Oxford Biomedical valued correctly by the market?

The company reported the revenue of 142.8 M. Net Income was 19.01 M with profit before overhead, payroll, taxes, and interest of 82.64 M.

Will Oxford Biomedical latest dip continue?

Latest jensen alpha is at -0.66. Oxford Biomedical exhibits very low volatility with skewness of -2.4 and kurtosis of 8.29. However, we advise investors to further study Oxford Biomedical technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oxford Biomedical's otc stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oxford Biomedical's otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Oxford Biomedical Implied Volatility

Oxford Biomedical's implied volatility exposes the market's sentiment of Oxford Biomedical stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Oxford Biomedical's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Oxford Biomedical stock will not fluctuate a lot when Oxford Biomedical's options are near their expiration.

Our Conclusion on Oxford Biomedical

Although many other companies in the biotechnology industry are either recovering or due for a correction, Oxford Biomedical may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 5th of July 2022, our analysis shows that Oxford Biomedical moves indifferently to market moves. The firm is undervalued and projects very low probability of financial unrest for the next 2 years. Our primary 90 days 'Buy-Sell' recommendation on the firm is Strong Hold.

Editorial Staff

Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Oxford Biomedical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC